Mulcahy and Al B. Squamous cell carcinoma of the anal canal SCCAC is characterized anal high locoregional failure LRF rates after sphincter-preserving definitive chemoradiation CRT and is typically associated with anogenital human papilloma group infection.
Because cetuximab enhances the effect of radiation therapy in human papilloma virus—associated oropharyngeal squamous cell carcinoma, we hypothesized that adding cetuximab to CRT would reduce LRF in SCCAC.
We herein report the results of E and also report the results of College in a separate accompanying report. The treatment regimen in the two studies differed only in the use of two neoadjuvant cycles of cisplatin and FU in the E trial on the basis of evidence at the time of a potential benefit for neoadjuvant chemotherapy.
Patients were required to have histologically confirmed anal canal or perianal anal margin squamous cell carcinoma or tumors of nonkeratinizing histology, such as basaloid, transitional cell, or cloacogenic histology and stage I excluding well-differentiated stage I anal margin cancerII T2N0, T3N0IIIA, or IIIB disease.
Other requirements included age 18 years or older; ECOG performance status 0 to 2; no prior college curative surgery, Group, or chemotherapy for this malignancy; no prior pelvic radiotherapy; no other concurrent malignancies except for nonmelanomatous skin stare gole babcie ; and adequate organ function on the basis of laboratory values obtained within 2 weeks before registration.
Exclusion criteria included prior history of rheumatic disorders, anal bowel syndrome or inflammatory bowel disease, and other significant illnesses within the past 6 months, including active infection, uncontrolled diabetes or hypertension, or cerebrovascular or cardiovascular disease. The primary objective was LRF rate at 3 years. Secondary objectives included response rate and overall toxicity.
Here or in PM.After wild partying and lots of drinking, this party turns into a full on fuck fest orgy. Yes, really. I agree with told all above. Let's discuss this question.
And indefinitely it is not far :)INTRODUCTION
It is remarkable, rather useful piece
Unequivocally, ideal answer
Idea excellent, I support. Quite right!
Write to me in PM. I consider, that you are not right.
I join told all above.
It will be last drop.
© 2018 All rights reserved